Skip to content
Study details
Enrolling now

Psilocybin on Brain Mechanisms of Motivation in OUD

Anna Rose Childress, Ph.D.
NCT IDNCT06810310ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

24

Study length

about 4 months

Ages

18–60

Locations

1 site in PA

What this study is about

This trial is testing whether psilocybin affects brain circuits related to motivation and addiction in people with opioid use disorder. Participants will receive either a low or high dose of psilocybin, followed by assessments using fMRI to examine brain activity before and after treatment.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Psilocybin (high dose)
  • 2.Take psilocybin (low dose)

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug routes

oral

Body systems

Psychiatry / Mental Health